BioSpace News Archive

Drug Development

Immunic’s DHODH Inhibitor Hits Mark in Phase II Multiple Sclerosis Trial

New York-based Immunic reported positive topline data from its Phase II EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis (RRMS).

August 3, 2020
·
3 min read
·
Mark Terry
Business

Johns Hopkins Outlines Public Health Challenges of Achieving Mass COVID-19 Vaccination

With billions of doses of COVID-19 vaccines expected to be available by year’s end, and a global population of 7.8 billion, public health officials are scrambling to deliver the vaccines in ways that are equitable and effective.

August 3, 2020
·
5 min read
·
Gail Dutton
Business

Regeneron and BioNTech Partner on Immunotherapy Combo for Melanoma

Regeneron Pharmaceuticals and BioNTech have inked a strategic collaboration to combine BioNTech’s BNT111 FixVac product candidate and Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab) for the treatment of melanoma.

August 3, 2020
·
2 min read
·
Mark Terry
Business

Russia Plans Mass COVID-19 Vaccination Program in October

Russia’s minister of health, Mikhail Murashko, indicated that the country plans a nationwide program to vaccinate its population against COVID-19 starting in October.

August 3, 2020
·
3 min read
·
Mark Terry
Policy

Biopharma Update on the Novel Coronavirus: August 3

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.

August 3, 2020
·
3 min read
·
BioSpace Editorial Staff
Drug Development

CymaBay Therapeutics’ PBC Treatment Hits the Mark in Phase III Study

Shares of CymaBay Therapeutics soared after the company announced its experimental primary biliary cholangitis (PBC) treatment seladelpar hit the mark in a Phase III study that sets up potential regulatory approval for this indication.

August 3, 2020
·
2 min read
·
Alex Keown
FDA

FDA Approves MorphoSys and Incyte’s DLBCL Drug Monjuvi

Eight months after inking a collaboration deal, MorphoSys and Incyte won approval for Monjuvi for adult patients with relapsed or refractory diffuse large B-cell lymphoma.

August 3, 2020
·
2 min read
·
Alex Keown
World’s First 3D Regenerative Implant and Regenerative Surgical Technique To Regrow Man’s Skull

Osteopore International Pte Ltd, a Singapore-headquartered company leading the way in regenerative bone implants, is proud to announce the success of its technology in a new medical procedure that took place in Brisbane, Australia, in December last year.

August 3, 2020
·
3 min read
Surface Plasmon Resonance (SPR) Market is Growing with Rising Adoption of Microfluidics Techniques

Surface Plasmon Resonance is a phenomenon of squeezing light to a tiny volume, causing biomolecules to get trapped across a surface, which in turn enables their study under a microscope.

August 3, 2020
·
10 min read
Bio NC

Verona Pharma Announces August 2020 Virtual Investor Conference Participation

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief Financial Officer, will present a company overview at the following virtual investor conferences in August 2020

August 3, 2020
·
2 min read